Media Thread, page-5130

For those trying to understand what this company is all about this is a great interview.
Leslie is her usual relaxed confident self and is afforded the time to communicate the innovative role Imugene is playing in the development of cancer treatment therapies.

There is so much to unpack, to understand and keep abreast of in the Imugene pipeline.
And as Equity Mates admit "this is a company I can't claim to understand" is a sentiment many will identify with.

So in a nutshell
we are the new kids on the block
we are a start up company that is really going to make a difference
developing novel therapies that haven't been explored before
working to change the paradigm of cancer treatment
modulating your own immune system to help fight cancer
developing vaccine and viral cancer therapies

Competition and the BioTech Industry
A key takeaway for me was Leslie's view on the competition and collaborative approach of Biotech
"we like to play nice, we don't consider anyone our competition ...
I actually love competition, you can build on the shoulders of giants
so when they win we win because that validates a certain target we are going after"

"The goal of every biotech company is not to obliterate the competition
but to provide another therapy line for our patients
all working together towards a better cure a better quality of life
better responses and durability for our cancer patients"

The Value of Imugene
"the long lasting value of Imugene is to really build our foundational science ...
follow the science the value will come
the science has to be realized by the patients"

Investment Potential
"the solid tumor market is huge
with our OnCARlytics there is really nothing like it in the world
we can infiltrate into every solid tumor and obliterate the cancer cells
the mark and kill approach, ... the durability and memory effect
this is the huge paradigm shift"

Competitive Advantage
"what differentiates Imugene is its safety profile
we think we can offer up the same level of efficacy
the same level of response even in combination"
The mitigation of side effects in drug combination

Thank you Leslie for being a wonderful CEO of Imugene
In my opinion this is a once in a lifetime investment opportunity.